GlaxoSmithKline Pharmaceuticals Limited (GLAXO)

Name: GlaxoSmithKline Pharmaceuticals Limited (GLAXO) — historial de estados financieros
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.

Healthcare · Wall Street (EE. UU.) · Última actualización: 2026-09-20

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix. It also provides respiratory specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease; and Seretide.

Cifras clave

Capitalización bursátil: ₹481 billion
Ingresos (ejercicio cerrado en 2026-03-31): ₹38.1B
Beneficio neto: ₹10.4B
Margen bruto: 62.7%
Margen neto: 27.2%

Ver gráficos interactivos y estados completos →

Cuenta de resultados anual

Cuenta de resultados	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Ingresos totales	₹38.1B	₹37.3B	₹34.4B	₹32.3B	—
Beneficio bruto	₹23.9B	₹22.5B	₹20.2B	₹18.7B	—
Ingresos operativos (EBIT)	₹12.5B	₹11.1B	₹8.4B	₹7.5B	—
Ingresos netos	₹10.4B	₹9.3B	₹5.9B	₹6.1B	—

Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.

Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de GLAXO. /companies/us/GLAXO

Empresas similares

La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.

English version →Todas las acciones

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.